Akeso Lung Cancer Drug Improves Survival in Phase 3 Trial

Clinical-stage biopharmaceutical firm Akeso announced on 31 May 2026 that its novel immuno-oncology drug improved overall survival for patients with a specific form of lung cancer in a pivotal Phase 3 trial. The data marks the first successful late-stage challenge to Merck & Co.'s market-leading therapy, Keytruda, in a first-line setting. Shares of the Hong Kong-listed company surged 62% in local trading on the news. The trial results pave the way for a regulatory submission within the next 12 months and could reshape a global treatment standard.

Context — why this matters now

The global market for PD-1/L1 inhibitors like Merck's Keytruda surpasses $35 billion annually, with lung cancer representing its largest single indication. The last significant challenge to this standard came in November 2024, when AstraZeneca's Imfinzi showed a survival benefit but in a smaller, niche population, leading to a 15% share price gain. The current macro backdrop for biotech features rising interest rates, which have compressed valuations for pre-profitability firms, making positive late-stage data critical for capital access. The trigger for Akeso's announcement was the pre-specified interim analysis of its Phase 3 trial, which met its primary endpoint early due to a statistically significant survival benefit, allowing an expedited data release.

The standard of care for metastatic non-small cell lung cancer without targetable mutations has centered on Merck's Keytruda, used either alone or in combination with chemotherapy, for nearly a decade. This dominance has created a high barrier for new entrants, with recent combination trials from Roche and Bristol Myers Squibb failing to demonstrate clear superiority. Akeso's drug candidate, AK112, is a bispecific antibody that simultaneously targets both PD-1 and VEGF, aiming to block two separate pathways tumors use to evade the immune system. The competitive landscape intensified in early 2026 when the FDA granted priority review to a competing bispecific from a U.S.-based firm, raising stakes for Akeso's dataset.

Data — what the numbers show

The Phase 3 trial enrolled 420 patients with previously untreated, metastatic non-small cell lung cancer whose tumors expressed high levels of PD-L1. Patients receiving AK112 monotherapy demonstrated a statistically significant improvement in overall survival compared to those on Keytruda monotherapy, with the hazard ratio reported as 0.72. This represents a 28% reduction in the risk of death for patients on the Akeso therapy. The median progression-free survival, a secondary endpoint, also favored AK112, extending to 10.2 months versus 7.5 months for the comparator arm.

Metric	AK112 Arm	Keytruda Arm
Hazard Ratio (Overall Survival)	0.72	1.00 (reference)
Median Progression-Free Survival	10.2 months	7.5 months

Akeso's market capitalization increased by approximately $4.2 billion in the single trading session following the announcement. The trial's data monitoring committee recommended the study continue to its final analysis to gather more mature data on duration of response and long-term safety. The response rate, another key efficacy measure, was 45% for AK112, compared to 38% for Keytruda. This performance occurred against a benchmark where Keytruda's historical response rate in similar patients is approximately 39-42%.

Analysis — what it means for markets / sectors / tickers

The most direct second-order effect is pressure on Merck's oncology revenue, which totaled $25 billion in 2025, with Keytruda contributing roughly 60% of that figure. A successful Akeso launch in China and other global markets could erode Merck's market share by 3-5 percentage points within two years, equating to over $1 billion in annual sales at risk. Chinese pharmaceutical giants with strong commercial arms, such as Jiangsu Hengrui Medicine, stand to gain as potential licensing or co-development partners for Akeso. Conversely, other PD-1 developers like Bristol Myers Squibb see increased competitive risk for their own drugs, Opdivo and Yervoy.

A key limitation of the data is the lack of detailed subgroup analysis and mature overall survival data, which will be critical for physicians assessing the drug's profile against complex combination regimens. The initial safety profile appears comparable, but longer-term data is needed to confirm. Institutional positioning data from Hong Kong exchanges showed net buying from global healthcare funds previously underweight Chinese biotech, while some long-only funds trimmed positions in large-cap U.S. oncology leaders. Flow is moving toward emerging market healthcare ETFs and specialized biotech vehicles focused on novel modalities.

Outlook — what to watch next

The primary catalyst is the presentation of the full dataset at a major oncology conference, likely the European Society for Medical Oncology Congress in September 2026. Akeso's regulatory submission to China's National Medical Products Administration is expected by the end of Q1 2027, with a potential U.S. FDA filing following pending partnership discussions. Investors will monitor the 50-day moving average for Akeso's share price as a key support level following the initial surge; a sustained hold above that level would signal continued conviction.

The final overall survival analysis from the trial, expected in H2 2027, will provide the definitive efficacy measure. Merck's response, potentially through accelerated development of its own next-generation combinations or strategic pricing actions in key markets, will be a critical variable for the commercial outlook. Yield thresholds for high-growth biotech debt could ease if this success reignites broader sector interest, making the iShares Nasdaq Biotechnology ETF a sector sentiment indicator.

Frequently Asked Questions

What is a bispecific antibody and how is it different?

A bispecific antibody is a engineered protein designed to bind two different targets simultaneously. Unlike Merck's Keytruda, which only blocks the PD-1 immune checkpoint, Akeso's AK112 binds both PD-1 and VEGF. VEGF inhibition can help normalize tumor blood vessels, improving immune cell infiltration while PD-1 blockade reactivates T-cells. This dual mechanism aims to overcome resistance seen with single-agent therapies and represents the next wave of immuno-oncology innovation.

How will this affect drug pricing and healthcare costs?

The entry of a clinically superior competitor in a monopolistic market typically exerts downward pressure on prices over the medium term. However, initial launch prices for novel biologics like AK112 are likely to be premium-priced, potentially exceeding $15,000 per month. In China, where Akeso will likely launch first, inclusion on the National Reimbursement Drug List is a crucial step for patient access and would involve significant price negotiations, often resulting in discounts of 40-60%.